Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BI-Lupin Deal To Up The Heat In Indian DPP-4 Market

This article was originally published in Scrip

Executive Summary

Innovator firms continue to tap into the marketing muscle of domestic companies as they vie for a bigger share of India's highly competitive dipeptidyl peptidase-4 (DPP-4) inhibitor market.

You may also be interested in...



Indian Teneligliptin Saga: Brands Bazaar, Surging Volumes

More than two dozen brands, a sharp spurt in sales volumes and a price decline of over 60% currently appear to characterize the market for the type 2 diabetes therapy teneligliptin in India. And market watchers claim that teneligliptin volumes in the country have surpassed the combined numbers of some of the more established gliptins, including vildagliptin and sitagliptin.

How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space

Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel